TrialRMD open2024

Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis.

Martin Rudwaleit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.